{
    "clinical_study": {
        "@rank": "45139", 
        "arm_group": [
            {
                "arm_group_label": "Germany", 
                "description": "A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL\u00ae or SEROQUEL\u00ae XR."
            }, 
            {
                "arm_group_label": "United Kingdom", 
                "description": "A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL\u00ae or SEROQUEL\u00ae XR."
            }, 
            {
                "arm_group_label": "Spain", 
                "description": "A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL\u00ae or SEROQUEL\u00ae XR."
            }, 
            {
                "arm_group_label": "Hungary", 
                "description": "A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL\u00ae or SEROQUEL\u00ae XR."
            }, 
            {
                "arm_group_label": "Netherlands", 
                "description": "A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL\u00ae or SEROQUEL\u00ae XR."
            }, 
            {
                "arm_group_label": "Sweden", 
                "description": "A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL\u00ae or SEROQUEL\u00ae XR."
            }, 
            {
                "arm_group_label": "Romania", 
                "description": "A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL\u00ae or SEROQUEL\u00ae XR."
            }, 
            {
                "arm_group_label": "Italy", 
                "description": "A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL\u00ae or SEROQUEL\u00ae XR."
            }
        ], 
        "brief_summary": {
            "textblock": "A physician survey to document receipt of metabolic educational materials and assess\n      behavior of physicians in following messages communicated through the educational materials"
        }, 
        "brief_title": "Physician Survey on Monitoring of Patients Treated With Quetiapine", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Schizophrenia", 
            "Bipolar Disorder", 
            "Major Depressive Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Depressive Disorder", 
                "Depression", 
                "Schizophrenia", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "Assessment of physician behavior regarding metabolic monitoring of patients treated with\n      SEROQUEL\u00ae   (quetiapine fumarate) Tablets and SEROQUEL\u00ae  (quetiapine fumarate) Extended\n      Release Tablets in selected countries in the EU"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Physicians targeted to receive the metabolic educational materials and either\n             currently prescribe or have the potential to prescribe SEROQUEL\u00ae  or SEROQUEL\u00ae  XR.\n\n        Exclusion Criteria:\n\n          -  Physicians who have participated in a survey involving SEROQUEL\u00ae / SEROQUEL\u00ae  XR in\n             the past six months are not eligible to participate in this survey."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "A sample of physicians who were targeted to receive the metabolic educational materials\n        and either currently prescribe or have the potential to prescribe SEROQUEL\u00ae  or SEROQUEL\u00ae\n        XR."
            }
        }, 
        "enrollment": {
            "#text": "800", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795326", 
            "org_study_id": "D1443C00127"
        }, 
        "intervention_browse": {
            "mesh_term": "Quetiapine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Effectiveness of risk minimization", 
            "Metabolic monitoring", 
            "Seroquel\u00ae", 
            "Seroquel\u00ae XR/quetiapine fumarate"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "number_of_groups": "8", 
        "official_title": "Assessment of Physician Behavior Regarding Metabolic Monitoring of Patients Treated With SEROQUEL\u00ae (Quetiapine Fumarate) Tablets and SEROQUEL\u00ae (Quetiapine Fumarate) Extended Release Tablets in Selected Countries in the EU", 
        "overall_official": {
            "affiliation": "AZ", 
            "last_name": "Robert S Brody, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: Medicines Evaluation Board (MEB)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Determination via survey whether physicians or someone in their practice perform monitoring of patients treated with Seroquel or Seroquel XR for metabolic issues related to treatment; refer their patients to another physician for monitoring.", 
                "safety_issue": "No", 
                "time_frame": "Over 6- 8 weeks."
            }, 
            {
                "measure": "Determination via survey whether physicians monitor tests for hyperlipidemia in patients who are taking Seroquel or Seroquel XR.", 
                "safety_issue": "No", 
                "time_frame": "Over 6- 8 weeks."
            }, 
            {
                "measure": "Determination via survey whether physicians monitor for signs and symptoms of  hyperglycemia in patients who are taking Seroquel or Seroquel XR.", 
                "safety_issue": "No", 
                "time_frame": "Over 6- 8 weeks."
            }, 
            {
                "measure": "Determination via survey whether physicians monitor blood glucose in patients with diabetes or monitor patients with risk factors for diabetes for worsening of glycemic control if they are taking Seroquel or Seroquel XR.", 
                "safety_issue": "No", 
                "time_frame": "Over 6- 8 weeks."
            }, 
            {
                "measure": "Determination via survey whether physicians monitor weight at initiation of treatment with Seroquel or Seoquel XR and on a regular basis after initiating treatment.", 
                "safety_issue": "No", 
                "time_frame": "Over 6- 8 weeks."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795326"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Determination via survey whether physicians counsel patients taking with Seroquel or Seroquel XR on healthy eating, exercise, and healthy lifestyle improvements.", 
                "safety_issue": "No", 
                "time_frame": "Over 6- 8 weeks."
            }, 
            {
                "measure": "Determination via survey whether physicians received educational information relevant to the issues in the survey from AstraZeneca.", 
                "safety_issue": "No", 
                "time_frame": "Over 6- 8 weeks."
            }, 
            {
                "measure": "Determination via survey whether physicians read the educational information.", 
                "safety_issue": "No", 
                "time_frame": "Over 6- 8 weeks."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}